[artículo] 
inJournal of Clinical Psychopharmacology > Año 2009 - Vol. 29 - No. 1 (Febrero) . - pp. 21-25

Título :	Polymorphisms of the lep- and lepr gene and obesity in patients using antipsychotic medication
Tipo de documento:	texto impreso
Autores:	Jochem G. Gregoor, Autor ; Jan van der Weide, Autor ; Hans Mulder, Autor
Fecha de publicación:	2022
Artículo en la página:	pp. 21-25
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Antipsicóticos, Obesidad, Aumento de peso, Farmacogenética, Polimorfismo, Leptina
Resumen:	Weight gain is one of the most serious adverse effects of atypical antipsychotic agents. Genetic factors influence the risk of an individual to gain weight. The objective of our study was to determine whether the LEPR Q223R polymorphism and the LEP promoter 2548G/A polymorphism are associated with obesity in a group of male and female patients using atypical antipsychotic drugs.
Link:	./index.php?lvl=notice_display&id=29524

[artículo] Polymorphisms of the lep- and lepr gene and obesity in patients using antipsychotic medication [texto impreso] / Jochem G. Gregoor, Autor ; Jan van der Weide, Autor ; Hans Mulder, Autor . - 2022 . - pp. 21-25.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2009 - Vol. 29 - No. 1 (Febrero) . - pp. 21-25

Palabras clave:	Antipsicóticos, Obesidad, Aumento de peso, Farmacogenética, Polimorfismo, Leptina
Resumen:	Weight gain is one of the most serious adverse effects of atypical antipsychotic agents. Genetic factors influence the risk of an individual to gain weight. The objective of our study was to determine whether the LEPR Q223R polymorphism and the LEP promoter 2548G/A polymorphism are associated with obesity in a group of male and female patients using atypical antipsychotic drugs.
Link:	./index.php?lvl=notice_display&id=29524